Advertisement

Topics

Xenome Limited Company Profile

22:48 EDT 24th September 2017 | BioPortfolio

Xenome aims to develop new treatments for pain, particularly intractable pain as experienced by many cancer patients, as well as other neurological conditions for which there is an unmet clinical need, e.g stroke.Xenome has an exclusive license to a collection of molecules and related technologies discovered by the Centre for Drug Design and Development (the Centre) at the University of Queensland (now part of the Institute for Molecular Bioscience). These molecules, know as conotoxins, were isolated from the venom of several species of cone shells collected from the Great Barrier Reef and have been shown to selectively inhibit proteins known as ion-channels. Inhibition of certain ion-channels is known to control various types of pain.

Xenome intends to test naturally occurring contoxins, as well as novel molecules, made chemically in the laboratory, for their pharmacological activity. Potentially useful molecules will then be tested in animal models for pain and other neurological conditions.

Location

Australia


News Articles [13 Associated News Articles listed on BioPortfolio]

Quotient Limited to Participate in the UBS Global Healthcare Conference

JERSEY, Channel Islands, May 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive O...

Oncobiologics announces strategic partnership with GMS Tenshi Holdings Pte. Limited

CRANBURY, N.J., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it entered into a Purchase Agreement on September 7, 2017 with GMS Tenshi Holdings Pte. Li...

Quotient Limited to Participate in the Jefferies 2017 Global Healthcare Conference

JERSEY, Channel Islands, May 31, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive O...

Quotient Limited to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference

JERSEY, Channel Islands, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive...

Kevin McCann and Mark Nelson Appointed to the Board of Directors of Telix Pharmaceuticals Limited

MELBOURNE, Australia, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix”, the “Company”) is pleased to announce that Mr. Kevin McCann AM and Dr. Mark Nelson have be...

Quotient Limited to Report Fourth Quarter and Fiscal Year 2017 Financial Results and Host Conference Call

JERSEY, Channel Islands, May 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and ...

Quotient Limited Reports Continued Progress on the Commercial Scale-up of MosaiQ and Fourth Quarter and Fiscal Year 2017 Financial Results

Initial MosaiQ manufacturing system commissioned and validatedFirst “commercially ready” MosaiQ Instrument delivered to QuotientInternal validation of MosaiQ underway, with EU field trials expe...

Quotient Limited Reports Results From Latest MosaiQ Performance Evaluation Studies Prior to Commencing Verification and Validation Studies

Performance evaluation studies confirm required concordance levels for all assaysVerification and validation studies to commence shortly European field trials still expected to be completed in CY17...

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [84 Associated Companies listed on BioPortfolio]

Xenome Limited

Xenome aims to develop new treatments for pain, particularly intractable pain as experienced by many cancer patients, as well as other neurological conditions for which there is an unmet clinical need...

Xenome Ltd

Xenome Ltd. was established to mine the diverse therapeutic potential of Australia's terrestrial and marine biota, to create a deep pipeline of potential solutions for unmet chronic conditions includi...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

SIEMENS CANADA LIMITED

More Information about "Xenome Limited" on BioPortfolio

We have published hundreds of Xenome Limited news stories on BioPortfolio along with dozens of Xenome Limited Clinical Trials and PubMed Articles about Xenome Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Xenome Limited Companies in our database. You can also find out about relevant Xenome Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...

Anesthesiology
An anesthesiologist (US English) or anaesthetist (British English) is a physician trained in anesthesia and perioperative medicine. Anesthesiologists are physicians who provide medical care to patients in a wide variety of (usually acute) situations. ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record